Imir Nilüfer Gülmen, Aydemir Esra, Şimşek Ece
Department of Biology Education, Akdeniz University, Antalya 07058, Turkey.
Life Sciences Institute, Department of Biology, Akdeniz University, Antalya 07058, Turkey.
Oncol Lett. 2018 Feb;15(2):2673-2678. doi: 10.3892/ol.2017.7604. Epub 2017 Dec 13.
Avemar, a derivative of fermented wheat germ extract, is a non-toxic and natural compound that is used as a dietary supplement by cancer patients undergoing chemotherapy and radiotherapy. Avemar has numerous biological activities, and several recent studies have reported that it may also have metastatic and anti-angiogenic effects. In the present study, the mechanism of the anti-angiogenic effect of Avemar on human cancer cells was investigated. The human cell lines NCI-N87 (gastric tubular adenocarcinoma), PC3 (prostate carcinoma), HeLa (endocervical adenocarcinoma) and A549 (lung adenocarcinoma) were treated with various doses (400, 800, 1,600 and 3,200 µg/ml) of Avemar, and the changes in mRNA and protein levels of two important markers of angiogenesis, vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (Cox-2), were assessed by reverse transcription-quantitative polymerase chain reaction and ELISA. VEGF and Cox-2 protein and mRNA levels were significantly lower in Avemar-treated cells than in untreated cells. The data suggest that Avemar may exert an anti-angiogenic effect on cancer cells. Thus, it is suggested to medical doctors as a potential agent for the anti-angiogenic treatment of cancer.
艾维玛（Avemar）是发酵小麦胚芽提取物的衍生物，是一种无毒的天然化合物，正接受化疗和放疗的癌症患者将其用作膳食补充剂。艾维玛具有多种生物活性，最近的几项研究报告称它可能还具有转移抑制和抗血管生成作用。在本研究中，对艾维玛对人癌细胞的抗血管生成作用机制进行了研究。用不同剂量（400、800、1600和3200µg/ml）的艾维玛处理人细胞系NCI-N87（胃管状腺癌）、PC3（前列腺癌）、HeLa（子宫颈腺癌）和A549（肺腺癌），并通过逆转录定量聚合酶链反应和酶联免疫吸附测定评估血管生成的两个重要标志物血管内皮生长因子（VEGF）和环氧化酶-2（Cox-2）的mRNA和蛋白质水平变化。经艾维玛处理的细胞中VEGF和Cox-2的蛋白质及mRNA水平显著低于未处理细胞。数据表明，艾维玛可能对癌细胞发挥抗血管生成作用。因此，建议医生将其作为癌症抗血管生成治疗的潜在药物。
